Building Bridges for Better Drug Development
We take a novel approach to drug development — building global teams and connecting data in ways you've never seen before.
Your Partner for Success
Fully-integrated to Accelerate Global Development of Novel Therapeutics.
Amador Bioscience bridges all stages and aspects of drug development. We offer a comprehensive range of services, encompassing translational science, clinical pharmacology, bioanalysis & biomarkers, regulatory strategy & submission, and clinical research adhearing to global standards.
We provide full-service clinical trial support (all under one roof!). Your project will be driven by a dedicated translational project manager and under the direct guidance of our extensive team of experts.
We’ll be with you every step of the way so you can focus on the outcomes: improving the lives of people everywhere.
At Amador Bioscience, we use science and experience to guide our decisions. From the very beginning, it was our ambition to build a powerful yet approachable team of top experts with a deep understanding of different aspects of the drug development process. Then, make those experts available to you as an extension of your team.
This approach originates from our strong belief that informed and evidence-based decision-making is vital in drug development, where the ultimate goal is saving and improving patients' lives. Our promise is to help you build the most efficient drug development program — without compromising on budget, timelines, or quality.
We support the success of your trial with a global network of therapeutic-specific key opinion leaders, subject-matter experts, vendors, and pre-qualified investigator trial sites. Our experts will help you bring new therapies to market safely and quickly in a number of therapeutic areas.
To leverage our expertise, reputation and business ecosystem to provide global-standard services to biopharmaceutical companies.
To become a leading global partner for biotherapeutics R&D success and become a leading global partner to the success of novel and improved biotherapeutics.